Table 3.
Ultrastaging of sentinel lymph node using H&E or H&E and IHC in patients with endometrial cancer
| Study | Year | Method of analysis | Nb of patients | FIGO stage | Macrometastatic SLN (%) | Micrometastatic SLN (%) |
|---|---|---|---|---|---|---|
| Burke | 1996 | H&E | 15 | I-II | 2 (13) | na |
| Echt | 1999 | H&E | 8 | I-IV | na | na |
| Holub | 2004 | H&E | 25 | I | 2 (8) | na |
| Raspagliesi | 2004 | H&E | 18 | I-III | 4 (22) | na |
| Altgassen | 2007 | H&E | 25 | I-II | 2 (8) | na |
| Frumovitz | 2007 | H&E | 18 | I-II-III | 0 | na |
| Li | 2007 | H&E | 20 | I-II-III | 2 (10) | na |
| Pelosi | 2003 | H&E+IHC | 16 | I | 3 18) | 3 (18) |
| Niikura | 2006 | H&E+IHC | 20 | I-II-III | 4 (20) | 4 (20) |
H&E: hematein eosin staining; IHC: immunohistochemy; SLN: sentinel lymph node; na: not available